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Since the early 1990s, extraordinary progress has been made in understanding the genetic basis 
of inherited cardiomyopathies enabling clinicians to perform genetic screening of the index 
patients and cascade screening in their families. More recently, the clinical implementation of 
next-generation sequencing techniques brought both the advantages and challenges of massive 
parallel sequencing of DNA to everyday practice. Indeed, the interpretation and implications 
of the sequencing results towards the patient and family poses a huge challenge to attending 
physicians. In this light, it is ever more crucial to exactly phenotype and study in depth the 
morphological and clinical aspects of the disease.
Morphological aspects
 For ACM, the fi rst detailed pathological description dates back to 18th century when René 
Laennec published his book ‘De l’auscultation me ‘diate ou traite ‘ du diagnostic des maladies 
des poumons et du coeur’ in 1819.1 In chapter XV on the accumulation of fat in the heart, he 
wrote ‘In medical writing we fi nd many examples of the heart being overloaded with fat [. . .] 
and even the sudden death [. . .] The fatter the heart is, the thinner [. . .] are its walls. Sometimes 
these are extremely thin, being reduced almost to nothing, especially at the apex of the heart 
and the posterior side of the right ventricle. [. . .] On examining ventricles [. . .] the scalpel seems to 
reach the cavity without encountering almost any muscular substance [. . .]’. The fi rst systematic 
description of morphologic abnormalities of ACM was by Thiene et al.2 investigating a series of 
young sudden deaths victims in the Veneto-region of Italy, where they recognized the disease as 
a major cause of cardiac arrest in the young with a particularly high occurrence in athletes. 
 In this thesis, we studied autopsy and explant heart specimen of PLN p.Arg14del 
mutation carriers with an ACM phenotype, in a similar way. We hypothesized, based on previous 
electrocardiographical and experimental fi ndings, that extensive myocardial fi brosis is present in 
both ventricles of mutation carriers and fi brosis to be a substrate for the ventricular arrhythmia and 
the progressive development of abnormalities in cardiac function. Macro- and microscopically we 
observed a biventricular phenotype with fi brofatty replacement, mainly in the RV wall, and the 
presence of fi brosis, mainly in the LV left posterior wall. The observed fi brofatty replacement did 
not diff er from that described in ACM due to mutations in desmosomal genes.3,4 Even in hearts in 
which the fi brofatty replacement was not obvious to the naked eye and only focally detectable by 
microscopy, we observed the distinct morphologic characteristics of ACM. In trichrome-stained 
tissue sections, there were foci with atrophic and hypertrophic cardiomyocytes, embedded in 
collagen and surrounded by fat cells.
Distinct molecular signature
We found phospholamban p.Arg14del cardiomyopathy to have a distinct molecular signature 
in comparison to desmosomal ACM. Plakoglobin redistribution, reduced SAP97 and abnormal 
GSK3β immunoreactive signal at myocyte intercalated disks, fi ndings consistently seen in 
desmosomal ACM,5-7 were observed only in the minority of PLN p.Arg14del cardiomyopathy 
cases. This is in line with previous observations in a similar biventricular ACM phenotype, caused 
by a desmoplakin truncating variant, where also no plakoglobin redistribution was observed. 
This suggests that diff erent signalling pathways are involved and therefore a diff erent molecular 
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signature is observed in classical right-dominant ACM and biventricular forms. 
 The precise pathophysiological mechanism of how the PLN p.Arg14del mutation leads 
to cardiac fibrosis and adiposis still needs to be elucidated. At the molecular level, coexpression 
of the normal and mutant PLN in HEK-293 cells results in reduced SERCA2a activity, an effect 
that leads to disturbed calcium metabolism of myocytes and cardiac dysfunction.8 In addition, 
overexpression of the PLN p.Arg14del mutation in transgenic mice causes extensive myocardial 
fibrosis8 and a dramatic increase in size of mouse hearts relative to PLN- wildtype controls.9 A 
tentative mechanism for the observed fibrofatty replacement and the subsequent clinical 
phenotype is the mechanical and electrical uncoupling of ventricular cardiomyocytes because 
of desmosomal instability. Desmosomes are proteins in the intercalated disk that connect 
adjacent cardiomyocytes, thereby providing mechanical integrity and electrical stability. Calcium 
homeostasis plays a critical role in maintaining desmosomal integrity.10 It is thus conceivable that 
the PLN p.Arg14del mutation causes cardiac desmosomal disintegration due to disturbed calcium 
handling. This is supported by the finding that plakoglobin is absent or diminished at intercalated 
disks in the majority of PLN p.Arg14del cardiomyopathy cases fulfilling ARVC criteria.11
 Furthermore, PLN p.Arg14del cardiomyopathy is characterized by large perinuclear PLN 
aggregates, aggresomes and autophagic degradation. These are detectable in complete heart 
specimens and myocardial tissue samples obtained from the apex of the left ventricle (LV) 
harvested during left ventricular assist device (LVAD) implantation but rarely in right ventricular 
endomyocardial biopsy samples. In clinical practice, PLN IHC analysis of LVAD specimens can be 
of incremental value in the diagnostic workup of this cardiomyopathy, even more so if genetic 
analysis is not readily available. We plan to further analyze the composition of the observed 
pathological protein aggregates. These results will hopefully contribute to a better understanding 
of the pathophysiological mechanisms involved and possibly lead to the development of 
therapeutic targets.
Fibrosis localisation: clinical utility roadmap
 The presence of myocardial fibrosis was found to be most pronounced subepicardially, 
as is seen more often in other nonischemic cardiomyopathies. This pattern contrasts with 
ischemic heart disease, where there is coronary artery-related distribution and where the 
subendocardial layer is usually involved with or without transmural extension.12,13 In human ACM, 
it is well known that cardiomyocytolysis and fibrofatty replacement progress from subepicardial 
and midmyocardial layers towards the endocardium.2,14 Experimental animal models have also 
shown that the disease process in ACM starts on the epicardial side and extends as a wave-front 
from the epicardium towards the endocardium.15 There is as yet no clear explanation for this 
apparent predilection of cardiomyopathic changes in the subepicardium but in PLN p.Arg14del-
related cardiomyopathy these histopathological changes may well be related to the disturbed 
interaction between mutated PLN and SERCA2a and differences in the regional expression of 
these proteins in the human heart. SERCA2a expression is higher in epicardial myocytes than in 
endocardial myocytes, whereas there appears to be no regional differences in PLN expression.16,17 
The transmural heterogeneity of SERCA2a expression and function is considered to be one of 
the factors underlying the variations in excitation-contraction coupling across the ventricular 
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wall, factors responsible for the 20-30 milliseconds delay in the onset of contraction of epicardial 
myocytes during every normal single heartbeat.
 With regard to regional diff erences in the presence of fi brosis, the inferolateral wall of the LV 
was found to be mostly aff ected. Indeed, also in our cardiac magnetic resonance (CMR) imaging 
study we observed that segments 5 and 11, corresponding with the LV inferolateral wall, were 
most profoundly aff ected. Most probably the higher vulnerability of the inferolateral LV free wall, 
and also the RV, to mechanical wall stress plays a role in this distribution18,19, in combination with 
regional molecular changes caused by the mutation. In a recent pathology study, the observed 
fi brosis pattern was found to be distinctive for PLN p.Arg14del cardiomyopathy in comparison 
with other hereditary cardiomyopathies.20 In a new CMR imaging study comprising a broader 
group of genotyped inherited cardiomyopathies we, together with the Academic Medical Center 
in Amsterdam, will further investigate these diff erences in fi brosis patterns. Furthermore, we plan 
to further investigate the correlation between radiology (CMR) and histology fi ndings in ACM 
subtypes.
Early myocardial fi brosis: canary in a coalmine?
Beside the distribution, the timing of occurrence of myocardial fi brosis in PLN p.Arg14del 
mutation carriers also seems to be distinctive: in previous studies low voltage and repolarization 
changes on the surface ECG, including the left lateral leads, were shown to be early hallmarks 
of PLN p.Arg14del cardiomyopathy.11,21 It was postulated that these features are a refl ection of 
fi brosis but this remained to be proven. 
 In our multicenter CMR imaging cohort, consisting of mainly presymptomatic mutation 
carriers, we indeed found myocardial fi brosis to be present in a large subgroup. Index patients 
showed more extensive structural and functional evidence of disease but fi brosis was also seen 
in many subjects with a preserved LV systolic function, which provides more evidence that the 
development of fi brosis occurs as an early phenomenon in PLN p.Arg14del mutation carriers. 
 Moreover, we found in a subgroup of presymptomatic PLN p.Arg14del mutation carriers 
early biventricular abnormalities using echocardiography: subtle but signifi cant structural 
remodeling as well as loss of LV diastolic early identifi cation of these features, and therefore of 
disease development and progression sometimes even before the onset of symptoms, may 
guide early therapeutic intervention and lifestyle adjustments (i.e. refraining from strenuous 
sports activity). This subsequently might prevent sudden cardiac death as a result of malignant 
ventricular arrhythmias and/or slow down progression of heart failure. 
 In a previous study by our group, it was shown that the occurrence of (non-)sustained 
VA and an LVEF of less than 45% (rather than 35%)22,23 is an independent risk factor for VA.24 
In this thesis, we refi ned this fi nding by showing that LV-LGE on CMR is an even stronger risk 
factor than LVEF. In fact, even in the setting of preserved LVEF, the mere presence of LV-LGE is 
associated with a higher risk of VA in PLN p.Arg14del mutation carriers. This is in line with previous 
studies showing LV-LGE on CMR imaging is an extra independent risk factor in selected groups of 
DCM-patients.25-29 Evenmore, we observed a clear trend towards incremental value of LV-LGE in 
prognostication of PLN p.Arg14del mutation carriers in a follow-up study of the CMR cohort. The 
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We strongly believe LV-LGE will be prove to be an important independent risk factor that can be 
used in daily clinical practice for treatment decisions. But to show this a longer follow-up period 
is required. These combined data support the early use of CMR with contrast-enhancement and 
echocardiography in this patient group, and should include the presymptomatic carriers. We will 
also implement these findings in the analysis of the iPHORECAST.
Preventive treatment: iPHORECAST
The iPHORECAST (intervention in PHOspholamban RElated CArdiomyopathy Study) is based on 
the observation of early presence of myocardial fibrosis in presymptomatic p.Arg14del mutation 
carriers. We hope to show that eplerenone, with its established antifibrotic effects, can reduce 
disease progression and postpone the onset of overt disease, comparable to a previous non-
randomized trial with diltiazem in hypertrophic cardiomyopathy.30 The inclusion of the first 
participant was May 13, 2014. A total of 82 participants were included in the 4 participating 
centers. Because of slow recruitment it was decided on April 1, 2017, to stop further inclusion of 
participants but to continue and complete the study with the included cohort. The follow-up, and 
collection of the follow-up data, is ongoing and will be finished around January 2021. By then we 
can evaluate the efficacy of pre- emptive eplerenone treatment in presymptomatic carriers. In the 
meantime we will evaluate baseline parameters and biomarkers, including biomarkers of fibrosis 
(e.g. N-terminal propeptide of procollagen type I (PINP), and N-terminal propeptide of collagen 
type III (PIIINP), to analyze their incremental value for the prediction of disease progression and 
cardiac events.
A distinct biventricular disease entity within the ACM spectrum 
More knowledge regarding the distinct features of PLN p.Arg14del cardiomyopathy may help 
us with the diagnosis, optimization of treatment and the understanding of the underlying 
pathophysiological mechanisms and natural course of this disease. The combination of (histo)
pathological, immunohistochemical, clinical and genetic findings in this thesis provide evidence 
for this disease to be a distinct biventricular disease entity within the ACM spectrum. Left 
ventricular involvement is typical in PLN p.Arg14del cardiomyopathy.20,31,32 Many symptomatic 
PLN p.Arg14del carriers have overlapping phenotypes and may fulfil international DCM criteria33 
and/or ARVC revised task force criteria.34 Task force criteria are only available for classical 
right-dominant ACM34, but are less suitable for left-dominant or biventricular subtypes.35 
Morphologically, heart specimens of PLN p.Arg14del mutation carriers show features of both 
ACM and DCM. This illustrates the overlap between different cardiomyopathy subtypes, i.e. ACM 
and DCM, and challenges the strict distinction made between them as two separate entities. 
Even more, this underscores the importance of a molecular diagnosis in patients with inherited 
cardiomyopathy. The distinct features of PLN p.Arg14del cardiomyopathy support the use of a 
descriptive classification system, i.e. MOGE(S) classification36, while waiting for further knowledge 
that may eventually support a genetic classification of cardiomyopathies, i.e. the ultimate intent 
of the AHA- and ESC classifications.
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